Status:
UNKNOWN
Retinol-binding Protein 4 (RBP4) Metabolizm in Type 2 Diabetes Progression and Associated Cardiovascular Complications
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Brief Summary
Retinol-binding protein 4 (RBP4) may affects obesity development and the development of obesity-related diseases including insulin resistance, type 2 diabetes, steatohepatitis and cardiovascular disea...
Detailed Description
A total of 500 Chinese patients admitted to the First Affliated Hospital of Xi'an Jiaotong University (Xi'an, China) between March 2020 and March 2022 were recruited to investigate the RBP4 profles. P...
Eligibility Criteria
Inclusion
- T2DM:
- Fasting plasma glucose (FPG)≥7.0 mmol/l;
- 2 h plasma glucose (2hPG) ≥11.1 mmol/l;
- glycated hemoglobin (HbA1c) level ≥6.5%;
- random plasma glucose ≥11.1 mmol/l plus symptoms of hyperglycemia;
- T2DM diagnosed previously.
- Pre-DM was defned as follows:
- FPG ≥5.6-6.9 mmol/l
- 2hPG 7.8-11.0 mmol/l
- HbA1c 5.7-6.4%.
Exclusion
- type 1 diabetes
- liver or kidney disorders.
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04325126
Start Date
April 1 2020
End Date
January 1 2023
Last Update
December 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710061